First Personalized Melanoma Vaccine Enters Phase 3 Trials in the UK
A new individualized mRNA-based melanoma vaccine is now in Phase 3 trials in the UK. The Phase 3 clinical trial, led by researchers at the University College London Hospitals NHS Foundation Trust (UCLH), is evaluating the combination of mRNA-4157 (V940) and pembrolizumab (Keytruda, Merck) versus a current standard of care (pembrolizumab) as a risk-reducing treatment […]